Olaparib maintenance versus placebo or standard of care in ovarian cancer: a biomarker-driven systematic review and meta-analysis of randomized trials.
Farida Namozova, Isadora Mamede, Carolina Alves Felippe et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of olaparib maintenance therapy in advanced ovarian cancer patients who responded to platinum-based chemotherapy. The analysis included eight randomized trials, revealing that olaparib significantly improved progression-free survival (PFS) compared to control (HR 0.48; 95% CI 0.37-0.62; p < 0.01), particularly in BRCA-mutated and HRD-positive patients.
Key findings
- Olaparib improved PFS compared to control with HR 0.48; 95% CI 0.37-0.62.
- The benefit was greater in BRCA-mutated patients (HR 0.33; 95% CI 0.22-0.52).
- Olaparib showed a trend toward improved overall survival (OS) with HR 0.82; 95% CI 0.66-1.02.
- Higher risk of grade ≥3 adverse events was noted, without significant increase in hematologic events.
Why it matters
The findings underscore the importance of biomarker selection in ovarian cancer treatment, as olaparib maintenance therapy offers significant benefits in specific patient subgroups, potentially guiding treatment decisions and improving patient outcomes.